NIH To Invest $577 Million In Nine Antiviral Drug Discovery Centers
"The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced last week that it was awarding about $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. A major goal of the centers, all of which are located at leading academic health centers and research institutions, is to develop drugs that can fight off the next pandemic."
"The targets include paramyxoviruses, bunyaviruses, togaviruses, filoviruses (including Ebola viruses and Marburg virus), picornaviruses (including enteroviruses and other cold-causing viruses), and flaviviruses (including the viruses that cause yellow fever, dengue and Zika)."
Brilacidin is not specifically mentioned, but many of the viral diseases listed have been reported to be sensitive to Brilacidin either by the virus or class of viruses or have been tested for sensitivity to Brilacidin.
From the 2022 Military symposium:
"Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.
The in vitro evaluation of Brilacidin’s antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin’s effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes."
https://www.ipharminc.com/press-release/2022/...-symposium
In addition as mentioned below we know Brilacidin was previously studied for:
"Testing in poxviruses builds on earlier NIH/NIAID-affiliated research of Brilacidin in other acutely infectious virus families, including coronaviruses, alphaviruses, flaviviruses, and filoviruses, with a corresponding scientific paper being prepared for publication. "
The Antiviral study centers is an old report, but I discovered it this AM is an old report.
GLTA,
Farrell
"The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced last week that it was awarding about $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. A major goal of the centers, all of which are located at leading academic health centers and research institutions, is to develop drugs that can fight off the next pandemic."
"The targets include paramyxoviruses, bunyaviruses, togaviruses, filoviruses (including Ebola viruses and Marburg virus), picornaviruses (including enteroviruses and other cold-causing viruses), and flaviviruses (including the viruses that cause yellow fever, dengue and Zika)."
Brilacidin is not specifically mentioned, but many of the viral diseases listed have been reported to be sensitive to Brilacidin either by the virus or class of viruses or have been tested for sensitivity to Brilacidin.
From the 2022 Military symposium:
"Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.
The in vitro evaluation of Brilacidin’s antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin’s effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes."
https://www.ipharminc.com/press-release/2022/...-symposium
In addition as mentioned below we know Brilacidin was previously studied for:
"Testing in poxviruses builds on earlier NIH/NIAID-affiliated research of Brilacidin in other acutely infectious virus families, including coronaviruses, alphaviruses, flaviviruses, and filoviruses, with a corresponding scientific paper being prepared for publication. "
The Antiviral study centers is an old report, but I discovered it this AM is an old report.
GLTA,
Farrell
7
